Literature DB >> 17851708

Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid-antibodies.

Hartwig W Lehmann1, Annelie Plentz, Philipp von Landenberg, Rolf-M Küster, Susanne Modrow.   

Abstract

Children with rheumatic oligo- and polyarthritis frequently establish persistent parvovirus B19 infections, which may be associated with the production of antiphospholipid antibodies. Reported in this paper are the data of five girls with polyarticular rheumatic diseases of different types and persistent parvovirus B19 infection associated in four cases with the presence of antibodies against phospholipids. Clinical parameters, virus load, and antiphospholipid-IgG levels were determined during an observation period up to 92 months. In two patients, erythema infectiosum preceded the development of arthritis and B19 viremia persisted. Two other girls showed antibodies against parvoviral structural proteins at time of the manifestation of the rheumatic disease. Subsequent samples also revealed persistent B19 infection. In the fifth patient, parvovirus B19-specific IgG antibodies were detected for the first time after 120 months of progressing disease at an age of 11 1/2 years. Five years later, quantitative polymerase chain reaction (PCR) revealed viral DNA. In a synovial tissue specimen subsequently obtained, parvovirus B19 structural proteins could be detected by immunohistochemistry. Three of five patients recovered completely without severe sequels. One patient is in remission under immunosuppressive therapy. The fifth patient suffers from progressive erosions despite intensive therapeutical efforts. In consequence, parvovirus B 19 should generally be taken into consideration as a trigger of various forms of juvenile arthritis and persistence of infection should be evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851708     DOI: 10.1007/s10067-007-0718-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  13 in total

1.  Clinical and epidemiological aspects of human parvovirus B19 infection in an urban area in Brazil (Niterói city area, State of Rio de Janeiro, Brazil).

Authors:  Solange Artimos de Oliveira; Luiz Antonio Bastos Camacho; Antonio Carlos de Medeiros Pereira; Tereza Filomena Faillace; Sérgio Setubal; Jussara Pereira do Nascimento
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-10       Impact factor: 2.743

2.  Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy.

Authors:  M Söderlund; R von Essen; J Haapasaari; U Kiistala; O Kiviluoto; K Hedman
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

3.  The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity.

Authors:  Simone Dorsch; Gerhard Liebisch; Bärbel Kaufmann; Philipp von Landenberg; Jörg H Hoffmann; Wolfgang Drobnik; Susanne Modrow
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 4.  Raynaud's phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes.

Authors:  L Harel; R Straussberg; H Rudich; A H Cohen; J Amir
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

5.  Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.

Authors:  Philipp Von Landenberg; Hartwig W Lehmann; Antje Knöll; Simone Dorsch; Susanne Modrow
Journal:  Arthritis Rheum       Date:  2003-07

Review 6.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

7.  Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence.

Authors:  Hartwig W Lehmann; Lucia Kühner; Karin Beckenlehner; Esther Müller-Godeffroy; Karl-Günter Heide; Rolf-Michael Küster; Susanne Modrow
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

8.  Human parvovirus B19-associated arthritis in children.

Authors:  J J Nocton; L C Miller; L B Tucker; J G Schaller
Journal:  J Pediatr       Date:  1993-02       Impact factor: 4.406

9.  Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.

Authors:  Hartwig W Lehmann; Antje Knöll; Rolf-Michael Küster; Susanne Modrow
Journal:  Arthritis Rheum       Date:  2003-06

10.  Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3.

Authors:  Lutz Liefeldt; Annelie Plentz; Boris Klempa; Olivia Kershaw; Anne-Sophie Endres; Ulla Raab; Hans-H Neumayer; Helga Meisel; Susanne Modrow
Journal:  J Med Virol       Date:  2005-01       Impact factor: 2.327

View more
  7 in total

1.  Chronic hepatitis caused by persistent parvovirus B19 infection.

Authors:  Trine H Mogensen; Jens Magnus B Jensen; Stephen Hamilton-Dutoit; Carsten S Larsen
Journal:  BMC Infect Dis       Date:  2010-08-20       Impact factor: 3.090

Review 2.  Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes.

Authors:  Debbie A Gladd; Ewa Olech
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

3.  Severe warm autoimmune haemolytic anaemia due to anti-Jk(a) autoantibody associated with Parvovirus B19 infection in a child.

Authors:  Gianluca Giovannetti; Simona Pauselli; Gianna Barrella; Alessia Neri; Loretta Antonetti; Giuseppe Gentile; Metello Iacobini; Gabriella Girelli; Serelina Coluzzi
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

Review 4.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 5.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

6.  The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis.

Authors:  Ori Elkayam; Daniele Bendayan; Refael Segal; Yinon Shapira; Boris Gilburd; Sandra Reuter; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Rheumatol Int       Date:  2012-08-04       Impact factor: 3.580

Review 7.  The Etiology of Juvenile Idiopathic Arthritis.

Authors:  Donato Rigante; Annalisa Bosco; Susanna Esposito
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 10.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.